Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 1
2017 8
2018 23
2019 30
2020 58
2021 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32518100

115 results
Results by year
Filters applied: . Clear all
Page 1
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Li J, et al. Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688. doi: 10.2215/CJN.02690320. Epub 2020 Jun 9. Clin J Am Soc Nephrol. 2020. PMID: 32518100 Review.
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. Circulation. 2019. PMID: 30786725
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
McKee A, Al-Khazaali A, Albert SG. McKee A, et al. J Endocr Soc. 2020 Mar 20;4(5):bvaa037. doi: 10.1210/jendso/bvaa037. eCollection 2020 May 1. J Endocr Soc. 2020. PMID: 32342023 Free PMC article. Review.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF, Buse JB, Mentz RJ, Holman RR. Clegg LE, et al. Cardiovasc Diabetol. 2019 Oct 22;18(1):138. doi: 10.1186/s12933-019-0942-x. Cardiovasc Diabetol. 2019. PMID: 31640705 Free PMC article.
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
DeFronzo RA. DeFronzo RA. Diabetes Obes Metab. 2017 Oct;19(10):1353-1362. doi: 10.1111/dom.12982. Epub 2017 Jun 7. Diabetes Obes Metab. 2017. PMID: 28432726 Free PMC article. Review.
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Tsapas A, Bekiari E. Mantsiou C, et al. Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14108. Online ahead of print. Diabetes Obes Metab. 2020. PMID: 32476254
Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG. Doumas M, et al. Curr Pharm Des. 2018;24(17):1879-1886. doi: 10.2174/1381612824666180604113653. Curr Pharm Des. 2018. PMID: 29865997 Review.
Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
Pinto LC, Rados DV, Remonti LR, Viana LV, Pulz GT, Carpena MP, Borges RP, Marobin R, Beretta MV, Pedrollo EF, Londero TM, Machry R, Janeczko L, Moehlecke M, Falcetta MR, Bauer AC, Silveiro SP, Gerchman F, Rodrigues TC, Kramer CK, Bertoluci MC, Leitão CB. Pinto LC, et al. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa534. doi: 10.1210/clinem/dgaa534. J Clin Endocrinol Metab. 2020. PMID: 32797182
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, Al-Aly Z. Xie Y, et al. Diabetes Care. 2020 Nov;43(11):2859-2869. doi: 10.2337/dc20-1890. Epub 2020 Sep 16. Diabetes Care. 2020. PMID: 32938746
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY, Petrie MC, McMurray JJV, Sattar N. Lee MMY, et al. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30. Arterioscler Thromb Vasc Biol. 2020. PMID: 31996025 Review.
115 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback